Tablets with AMD Accelerated Processors Z-60 1.0GHz 2 cores 4.5W TDP 1MB cache 80 Radeon cores, 275MHz GPU DirectX 11 UVD 3 DDR3-1066/DDR3L-1066
Meet AMD’s new tablet APU: The Z-60 delivers Radeon graphics for Windows 8 touch
Atom (system on chip) in tablet
Z2760 with PowerVR 545 support DirectX 10.1 for Windows 8
1366x768, 64GB, microUSB
ASUS VivoTab Smart 10.1", 8MP, 2MP, microSD, NFC, 25Wh, 8.5hr, 580g, 9.7mm
*ASUS VivoTab 11.6", 8MP, 2MP, microSD, Wacom digitizer stylus, NFC, 30Wh, 10.5hr, 675g, 8.7mm
HP Envy X2 11.6", 8MP, webcam, USB, 802.11 abgn, NFC, 25Wh, 7hr, keyboard, 1393g, 19.3mm
Dell Latitude 10 10.1" Gorilla, 8MP, 2MP, Wacom Stylus, SD, USB, 30Wh, 890g, 13.1mm
*Lenovo Ideatab Lynx 11.6", no back camera, 2MP, microSD, microUSB 8hr 640g, 9.4mm
*Samsung ATIV 11.6", 8MP, 2MP, S Pen digitizer, microSD, USB, 802.11 abgn, 30Wh, 9.7hr, 759g, 9.9mm
Acer Iconia W510, 10.1" 32GB, microSD, 802.11 abgn, 3.54mAh, 9hr, 580g, 7.6mm
Acer Iconia W3 8.1" TFT (not IPS) 1280x800, 32GB, microSD, microUSB 8hr, 500g, 10.2mm
Intel Atom Processor For Tablet Z2760 1.8GHz 2 cores 4 threads 1.7W TDP 1MB cache 533MHz GPU
Intel Atom Z2460 (1.6Ghz) Medfield is old generation.
Intel Accelerates Mobile Computing Push 32nm: Z2420 (1.2Ghz), Z2520 (1.2Ghz), Z2540 (1.6Ghz), Z2580 (2.0Ghz), Z2760 (1.8Ghz)
Friday, March 08, 2013
Tom's Hardware Graphics Card Hierarchy Chart
Tom's Hardware Graphics Card Hierarchy Chart
POWER SUPPLY REQUIREMENT FOR GRAPHICS CARDS
nVidia, AMD, benchmark, GPU ranking, video cards ranked
AMD Radeon 5770
260X $80
7770 $75
7750 $50
nvidia GeForce 640 $40
nvidia GeForce 650 $70
AMD Radeon 6450 fanless $20
2GB fanless from Newegg GeForce 630 (CUDA 2.1), Radeon HD 6450 (no double-precision)
Double precision GPU
List of AMD graphics processing units Radeon HD 38xx, 47xx, 58xx, 69xx, 77xx, 85xx, R7, R9
3830 (3850) 85.4Gflops OpenCL 1.0 75W 2008
7730 44.8Gflops OpenCL 1.2 47W 10W 2013
R7 240 29.2Gflops OpenCL 1.2 30W 2013
List of Nvidia graphics processing units CUDA-supported GPU nvidia developer cuda gpus compute capability 1.3 GeForce GTX, GT 430+, GTS 450
Fanless double-precision on Newegg
GT 630, GT 730 is very efficient 27.67 Gflops/W
HD 5770 GDDR5 (PCIE2.1x16) +- 0
R7 250 GDDR5 ($90,PCIE3.0x2) -3
GT 640 DDR3 ($104,PCIE3.0x2) -2
R7 240 DDR3 ($70,low,PCIE3.0x2) -2(-1,-0)
GT 630 r2 = 730 DDR3 ($45,low,PCIE2.0) -3(-4,-5)
HD 6450 ($20,low,PCIE2.1) -2
GT 520M (Thinkpad T520)
Distributed computing:
1. Boinc GPU computing, BOINC Credit System, computation credits, cobblestone point
Milkyway gpu list double-precision
GPU Grid gpu list only on CUDA 1.3+, GT630 is slow
PrimeGrid gpu list both CPU and GPU work units
select these work units: low (Recent averagetime)/(Deadline): PPS (2hr), MEGA (5hr), PPSE (:40), SR5 (:40), GFN-Short (GPU)
(1.000) GeForce GTS Titan Black
(0.103) ATI Radeon HD 5770
(0.027) GeForce GT 630
(0.019) AMD Radeon HD 6350/6450/7450/7470 series (Caicos)
Bitcoin Utopia account problem
Seti@Home gpu list OpenCL 1.2
Moo Wrap gpu list account problem
Collatz Conjecture gpu list
Free Rainbow Tables gpu list DistrRTgen
For CPU: Asteroids@home, NumberFirlds@home, PrimeGrid
1. Free-DC statistics for Boinc@Taiwan: Top 10 to join: NumberFields@home (CPU), DistrRTgen (GPU)
Need help SETI@Home
New: Spatiotemporal Quality of Service
2. Boincstats Boinc@Taiwan
Team Boinc@Taiwan
如果您有nvidia的顯卡，請加入PrimeGrid專案或DistrRTgen專案。
如果您有AMD-ATi的顯卡，請加入Moo! Wrapper專案或Collatz Conjecture專案。
如果您有HD7970的顯卡，請加入 DistrRTgen 專案。
如果您沒有顯卡，請加入PrimeGrid專案或DistrRTgen專案。
2. Stanford Research Protein Folding@Home Chrome App, Points per day (PPD), Points TPF
Chrome Chromium browser Native Client NaCl (salt)
Taiwan Team #31403
Extreme Overclocking list of top taiwan members, 24 hr change, 7 day change
extremeoverclocking user stat
Kakao Stats, Update, 24 hrs, 7 days
3. distributed.net GPU speed
4. Great Internet Mersenne Prime Search GIMPS OpenCL clients, CUDA clients
POWER SUPPLY REQUIREMENT FOR GRAPHICS CARDS
nVidia, AMD, benchmark, GPU ranking, video cards ranked
AMD Radeon 5770
260X $80
7770 $75
7750 $50
nvidia GeForce 640 $40
nvidia GeForce 650 $70
AMD Radeon 6450 fanless $20
2GB fanless from Newegg GeForce 630 (CUDA 2.1), Radeon HD 6450 (no double-precision)
Double precision GPU
List of AMD graphics processing units Radeon HD 38xx, 47xx, 58xx, 69xx, 77xx, 85xx, R7, R9
3830 (3850) 85.4Gflops OpenCL 1.0 75W 2008
7730 44.8Gflops OpenCL 1.2 47W 10W 2013
R7 240 29.2Gflops OpenCL 1.2 30W 2013
List of Nvidia graphics processing units CUDA-supported GPU nvidia developer cuda gpus compute capability 1.3 GeForce GTX, GT 430+, GTS 450
Fanless double-precision on Newegg
GT 630, GT 730 is very efficient 27.67 Gflops/W
HD 5770 GDDR5 (PCIE2.1x16) +- 0
R7 250 GDDR5 ($90,PCIE3.0x2) -3
GT 640 DDR3 ($104,PCIE3.0x2) -2
R7 240 DDR3 ($70,low,PCIE3.0x2) -2(-1,-0)
GT 630 r2 = 730 DDR3 ($45,low,PCIE2.0) -3(-4,-5)
HD 6450 ($20,low,PCIE2.1) -2
GT 520M (Thinkpad T520)
Distributed computing:
1. Boinc GPU computing, BOINC Credit System, computation credits, cobblestone point
GPU Grid gpu list only on CUDA 1.3+, GT630 is slow
PrimeGrid gpu list both CPU and GPU work units
select these work units: low (Recent averagetime)/(Deadline): PPS (2hr), MEGA (5hr), PPSE (:40), SR5 (:40), GFN-Short (GPU)
(1.000) GeForce GTS Titan Black
(0.103) ATI Radeon HD 5770
(0.027) GeForce GT 630
(0.019) AMD Radeon HD 6350/6450/7450/7470 series (Caicos)
Bitcoin Utopia account problem
Seti@Home gpu list OpenCL 1.2
Moo Wrap gpu list account problem
Collatz Conjecture gpu list
Free Rainbow Tables gpu list DistrRTgen
For CPU: Asteroids@home, NumberFirlds@home, PrimeGrid
1. Free-DC statistics for Boinc@Taiwan: Top 10 to join: NumberFields@home (CPU), DistrRTgen (GPU)
Need help SETI@Home
New: Spatiotemporal Quality of Service
2. Boincstats Boinc@Taiwan
Team Boinc@Taiwan
如果您有nvidia的顯卡，請加入PrimeGrid專案或DistrRTgen專案。
如果您有AMD-ATi的顯卡，請加入Moo! Wrapper專案或Collatz Conjecture專案。
如果您有HD7970的顯卡，請加入 DistrRTgen 專案。
如果您沒有顯卡，請加入PrimeGrid專案或DistrRTgen專案。
2. Stanford Research Protein Folding@Home Chrome App, Points per day (PPD), Points TPF
Chrome Chromium browser Native Client NaCl (salt)
Taiwan Team #31403
Extreme Overclocking list of top taiwan members, 24 hr change, 7 day change
extremeoverclocking user stat
Kakao Stats, Update, 24 hrs, 7 days
3. distributed.net GPU speed
4. Great Internet Mersenne Prime Search GIMPS OpenCL clients, CUDA clients
Thursday, March 07, 2013
Trademark
Trademarks Search Wines and Spirits Products (Alcoholic beverages)
Junior Johnson’s Midnight Moon North Carolina
Ole Smoky Tennessee Moonshine Tennessee
Stillhouse Distillery: The Original Moonshine Clear Corn Whiskey Virginia
Wicked Tango: Wicked Lightning Moonshine Colorado
Firefly Distillery Firefly Moonshine South Carolina
Canada Kealy's Moonshine British Columbia
Junior Johnson’s Midnight Moon North Carolina
Ole Smoky Tennessee Moonshine Tennessee
Stillhouse Distillery: The Original Moonshine Clear Corn Whiskey Virginia
Wicked Tango: Wicked Lightning Moonshine Colorado
Firefly Distillery Firefly Moonshine South Carolina
Canada Kealy's Moonshine British Columbia
Wednesday, March 06, 2013
Auto Sales Data
中時旺車 汽車銷售每月排行 Monthly Sales Ranking
U-Car 銷售排行 - 最新市場銷售報告 Market Report
雅虎奇摩 汽車 新車銷售排行榜 Yahoo!
GOOD CAR BAD CAR Passionate Tracking Of Auto Sales Data
U-Car 銷售排行 - 最新市場銷售報告 Market Report
雅虎奇摩 汽車 新車銷售排行榜 Yahoo!
GOOD CAR BAD CAR Passionate Tracking Of Auto Sales Data
Laxative for Constipation
Laxative
Comparison of constipation treatments
IBS irritable bowel syndrome, diarrhea and/or constipation
Bulk-forming, comparison
Bran (insoluble fibre), Gamkaraya, Sterculia[Normacol], psyllium husk (Metamucil (soluble fiber)) [causing gas bloating, lowing cholesterol], methylcellulose (Citrucel), polycarbophil calcium (FiberCon), dietary fiber, apples (soluble fiber), broccoli, prunes (soluble fiber).
Fiber Foods Grouped by Fiber Content per Serving: beans (pinto, navy, kidney), all bran cereal, spinach, greens
Comparison of constipation treatments
IBS irritable bowel syndrome, diarrhea and/or constipation
-- Over-the-counter enzyme supplements (dairy products, beans)
-- enteric-coated peppermint oil capsules, psyllium fiber supplements
-- probiotic supplements
- Monash, FODMAP: fermentable oligosaccharides 寡醣 (FOS 果寡糖 onion/leak/asparagus, GOS 半乳寡糖 beans), disaccharides 雙醣 (lactose 乳糖), monosaccharides 單醣 (fructose 果糖), and polyols 多元醇 (sugar alcohol 糖醇 -itol). erythritol 赤藻糖醇/赤蘚醇 4-carbon is better than xylitol 木糖醇 5-C > sorbitol 山梨醇 6-C
non-fodmap diet sugar (Sucralose Splenda, Aspartame Equal NutraSweet, Saccharin Sweet'n Low)
Fleet Bisacodyl Enema 10mg 30ml
Stimulants not for long term
Senokot (senna glycosides, sennosides)
* Dulcolax Laxative Tablets Bisacodyl 5mg
Phillips Magnesium hydroxide
Stool Softeners, Emollients for prevention, not for long term
* Docusate sodium
Fleet Bisacodyl Enema 10mg 30ml
Senokot (senna glycosides, sennosides)
* Dulcolax Laxative Tablets Bisacodyl 5mg
Hydrating agents (osmotics)
Miralax Polyethylene Glycol PEG MacrogolPhillips Magnesium hydroxide
Stool Softeners, Emollients for prevention, not for long term
* Docusate sodium
Bulk-forming, comparison
Bran (insoluble fibre), Gamkaraya, Sterculia[Normacol], psyllium husk (Metamucil (soluble fiber)) [causing gas bloating, lowing cholesterol], methylcellulose (Citrucel), polycarbophil calcium (FiberCon), dietary fiber, apples (soluble fiber), broccoli, prunes (soluble fiber).
Fiber Foods Grouped by Fiber Content per Serving: beans (pinto, navy, kidney), all bran cereal, spinach, greens
Saturday, March 02, 2013
Iron Rich Snacks
Top 10 Foods Highest in Iron
Nutrition in 100g
Pumpkin Seeds 南瓜子 15mg
Sesame Seeds 芝麻 14.5mg
Watermelon Seeds 瓜子 7.3mg
Beef Jerky 牛肉乾 5.4mg
Sunflower Seeds 葵花子 4.3mg
Almonds 杏仁 3.7mg
Raisins 葡萄乾 1.9mg
Firm Tofu 硬豆腐, 豆干 1.6mg
Peanuts 花生 1.5mg
Prunes Dried Plums 黑棗乾 0.9mg
Nutrition in 100g
Pumpkin Seeds 南瓜子 15mg
Sesame Seeds 芝麻 14.5mg
Watermelon Seeds 瓜子 7.3mg
Beef Jerky 牛肉乾 5.4mg
Sunflower Seeds 葵花子 4.3mg
Almonds 杏仁 3.7mg
Raisins 葡萄乾 1.9mg
Firm Tofu 硬豆腐, 豆干 1.6mg
Peanuts 花生 1.5mg
Prunes Dried Plums 黑棗乾 0.9mg
Tuesday, February 26, 2013
Saturday, February 23, 2013
Cloud Service Status and Pricing
Software as a service (SaaS)
Amazon Web Services Service Health Dashboard (AWS Status)
Microsoft Windows Live Service Status
Google Apps Status Dashboard
Google Apps Engine server Status
Apple Services, Stores, and iCloud (System Status)
Microsoft Windows Azure Service Dashboard (Current Status)
Box Status
Dropbox status
1. Microsoft Office 365 5TB/5 users $60/year
2. Microsoft OneDrive for Business 1TB $30/year
3. Microsoft Office 365 1TB $100/year
4. Google Drive 1TB $120/year
Amazon Cloud Drive Unlimited Photos $12/year, Unlimited Everything $60/year
Google Drive Storage plan pricing 15GB free, every 1TB $9.99 monthly, $0.12/GB/year
Microsoft OneDrive plans 15GB free, every 100GB $1.99/month, $0.24/GB/year, business 1TB $30/year, $0.03/GB/year
Microsoft Office 365 1TB*5 $100/year, $0.02/GB/year, small business 1TB/user $60/year $0.06/GB/year
iCloud Drive storage plans 5GB free, extra 20GB $12 yearly, 200GB $48/year, $0.24/GB/year
Dropbox Pricing 2GB free, 100GB $9.99/month $99/year, $1.0/GB/year
Box pricing 10GB free, 100GB $5/month, $0.6/GB/year, unlimited $15/month
MultiCloud File Manager
Amazon Web Services Service Health Dashboard (AWS Status)
Microsoft Windows Live Service Status
Google Apps Status Dashboard
Google Apps Engine server Status
Apple Services, Stores, and iCloud (System Status)
Microsoft Windows Azure Service Dashboard (Current Status)
Box Status
Dropbox status
1. Microsoft Office 365 5TB/5 users $60/year
2. Microsoft OneDrive for Business 1TB $30/year
3. Microsoft Office 365 1TB $100/year
4. Google Drive 1TB $120/year
Amazon Cloud Drive Unlimited Photos $12/year, Unlimited Everything $60/year
Google Drive Storage plan pricing 15GB free, every 1TB $9.99 monthly, $0.12/GB/year
Microsoft OneDrive plans 15GB free, every 100GB $1.99/month, $0.24/GB/year, business 1TB $30/year, $0.03/GB/year
Microsoft Office 365 1TB*5 $100/year, $0.02/GB/year, small business 1TB/user $60/year $0.06/GB/year
iCloud Drive storage plans 5GB free, extra 20GB $12 yearly, 200GB $48/year, $0.24/GB/year
Dropbox Pricing 2GB free, 100GB $9.99/month $99/year, $1.0/GB/year
Box pricing 10GB free, 100GB $5/month, $0.6/GB/year, unlimited $15/month
MultiCloud File Manager
Tuesday, February 19, 2013
Taiwan Chinese Mandarin Summer Camp
Summer Vacation, foreign students
夏令營相關資訊
Connexpedition WCEO 2/5 Wisdom Culture and Education Organization, currently in high school 9-12, Sunday training
Vox Nativa 7/7-23 17 days, $870
New Taipei City 6/28-7/14/2018 17 days, $450 新北市 EASY LEAP 英語輔學營
僑務委員會 華裔青年返國研習
* 海外華裔青年英語服務營, Overseas Youth English Teaching Volunteer Service Program Grade 11 when apply, 17-25, 6/30-7/28/2018, 4 weeks
海外華裔青年語文研習班 14-18, 6 weeks $18000
海外華裔青年臺灣觀摩團 Study Tour Programs for Overseas Youth Love Boat (study tour) 16-27,
瘋華語夏令營 2011 7-12yr, 13-16yr, 7/1-27, 7/15-8/10, 4 weeks $48000 $89000(住宿班)
師範大學 華語夏令營 8-11yr, 12-15yr, 6/17-7/12, 7/15-8/9, 4 weeks $44500 $43000(救國團中國青年旅行社 12+ 7/15-8/9)
中國文化大學 華語中心 海外兒童&青少年華語夏令營 7-9yr, 10-15yr, 7/8-26, 7/29-8/16, 3 weeks $19500 $33000(12+ 團體住宿) $10500(14+ 寄宿家庭)
國語日報社 華語文中心 暑期華語研習營 6-15, 6/10-28 $25000, 7/1-31 $36000, 8/1-30 $28000, 3-4.5 weeks
國立臺北教育大學 華語文中心 暑期海外兒童及青少年華語夏令營 6-15yr, 6/24-7/19yr, 7/22-8/16yr, 4 weeks $34750
復興高中 華語夏令營 Grade 2-6, 7/8-26, 3 weeks $31000
國科會 候鳥計畫 18-30, finished 2 years college
Taiwanese American Youth Leadership - Leading Youth Forward entering grade 5-12
夏令營相關資訊
Connexpedition WCEO 2/5 Wisdom Culture and Education Organization, currently in high school 9-12, Sunday training
Vox Nativa 7/7-23 17 days, $870
New Taipei City 6/28-7/14/2018 17 days, $450 新北市 EASY LEAP 英語輔學營
僑務委員會 華裔青年返國研習
* 海外華裔青年英語服務營, Overseas Youth English Teaching Volunteer Service Program Grade 11 when apply, 17-25, 6/30-7/28/2018, 4 weeks
海外華裔青年語文研習班 14-18, 6 weeks $18000
海外華裔青年臺灣觀摩團 Study Tour Programs for Overseas Youth Love Boat (study tour) 16-27,
- 救國團 FUN 遊福爾摩莎 華裔青少年台灣觀摩夏令營 2015 12-20, 7/1-21, 21 days or 7/6-21, 16 days $1245(2人房), 21 days $1525
師範大學 華語夏令營 8-11yr, 12-15yr, 6/17-7/12, 7/15-8/9, 4 weeks $44500 $43000(救國團中國青年旅行社 12+ 7/15-8/9)
中國文化大學 華語中心 海外兒童&青少年華語夏令營 7-9yr, 10-15yr, 7/8-26, 7/29-8/16, 3 weeks $19500 $33000(12+ 團體住宿) $10500(14+ 寄宿家庭)
國語日報社 華語文中心 暑期華語研習營 6-15, 6/10-28 $25000, 7/1-31 $36000, 8/1-30 $28000, 3-4.5 weeks
國立臺北教育大學 華語文中心 暑期海外兒童及青少年華語夏令營 6-15yr, 6/24-7/19yr, 7/22-8/16yr, 4 weeks $34750
復興高中 華語夏令營 Grade 2-6, 7/8-26, 3 weeks $31000
Taiwanese American Youth Leadership - Leading Youth Forward entering grade 5-12
Wednesday, February 13, 2013
Complementary and Alternative Medicine
National Cancer Institute: Complementary and Alternative Medicine (CAM)
*PDQ Cancer Information Summaries: Complementary and Alternative Medicine 713-X, Acupuncture, Antineoplastons, Aromatherapy and Essential Oils, Cancell/Cantron/Protocel, Cannabis and Cannabinoids, Cartilage (Bovine and Shark), Coenzyme Q10, Essiac/Flor Essence, Gerson Therapy, Gonzales Regimen, High-Dose Vitamin C, Hydrazine Sulfate, Laetrile/Amygdalin, Milk Thistle, Mistletoe Extracts, Newcastle Disease Virus, PC-SPES, Prostate Cancer, Nutrition, and Dietary Supplements, Selected Vegetables/Sun's Soup, Spirituality in Cancer Care
National Center for Complementary and Alternative Medicine (NCCAM): Cancer Prevention and Treatment
American Cancer Society » Treatments and Side Effects » Complementary and Alternative Medicine
*American Cancer Society » Treatments and Side Effects » Complementary and Alternative Medicine » Diet and Nutrition Acidophilus, Broccoli, Cassava, Coriolus Versicolor, Ellagic Acid, Fasting, Garlic, Gerson Therapy, Grapes, Inositol Hexaphosphate, Juicing, Kombucha Tea, Lycopene, Macrobiotic Diet, Maitake Mushrooms, Metabolic Therapy, Modified Citrus Pectin, Nori Plant, Omega-3 Fatty Acids, Quercetin, Sea Vegetables, Shiitake Mushroom, Soybean, Vegetarianism, Wheatgrass
Memorial Sloan-Kettering Cancer Center: Integrative Medicine About Herbs, Botanicals & Other Products
WebMD: Vitamins Supplements: Condition Ovarian Cancer Beta-Carotene, Black Tea, Ginkgo, Green Tea, Lycopene, Oolong Tea, Quercetin, Tomato, Vitamin A, Vitamin C (Ascorbic Acid)
Supplements that help fighting ovarian cancer
Ovarian cancer and mushroom, fruit, vegetable, preserved food, tea consumption, lactation, labitual physical activity, soy, isoflavone, dietary folate
Organic Production Enhances Milk Nutritional Quality by Shifting Fatty Acid Composition Omega 3 Fatty Acid
High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy
Turmeric: Curcumin
*PDQ Cancer Information Summaries: Complementary and Alternative Medicine 713-X, Acupuncture, Antineoplastons, Aromatherapy and Essential Oils, Cancell/Cantron/Protocel, Cannabis and Cannabinoids, Cartilage (Bovine and Shark), Coenzyme Q10, Essiac/Flor Essence, Gerson Therapy, Gonzales Regimen, High-Dose Vitamin C, Hydrazine Sulfate, Laetrile/Amygdalin, Milk Thistle, Mistletoe Extracts, Newcastle Disease Virus, PC-SPES, Prostate Cancer, Nutrition, and Dietary Supplements, Selected Vegetables/Sun's Soup, Spirituality in Cancer Care
National Center for Complementary and Alternative Medicine (NCCAM): Cancer Prevention and Treatment
American Cancer Society » Treatments and Side Effects » Complementary and Alternative Medicine
*American Cancer Society » Treatments and Side Effects » Complementary and Alternative Medicine » Diet and Nutrition Acidophilus, Broccoli, Cassava, Coriolus Versicolor, Ellagic Acid, Fasting, Garlic, Gerson Therapy, Grapes, Inositol Hexaphosphate, Juicing, Kombucha Tea, Lycopene, Macrobiotic Diet, Maitake Mushrooms, Metabolic Therapy, Modified Citrus Pectin, Nori Plant, Omega-3 Fatty Acids, Quercetin, Sea Vegetables, Shiitake Mushroom, Soybean, Vegetarianism, Wheatgrass
Memorial Sloan-Kettering Cancer Center: Integrative Medicine About Herbs, Botanicals & Other Products
WebMD: Vitamins Supplements: Condition Ovarian Cancer Beta-Carotene, Black Tea, Ginkgo, Green Tea, Lycopene, Oolong Tea, Quercetin, Tomato, Vitamin A, Vitamin C (Ascorbic Acid)
Supplements that help fighting ovarian cancer
Ovarian cancer and mushroom, fruit, vegetable, preserved food, tea consumption, lactation, labitual physical activity, soy, isoflavone, dietary folate
Organic Production Enhances Milk Nutritional Quality by Shifting Fatty Acid Composition Omega 3 Fatty Acid
High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy
Turmeric: Curcumin
Tuesday, January 22, 2013
Monday, January 14, 2013
Thursday, January 10, 2013
台灣百貨公司
台灣百貨列表 Taiwan Department Stores 日系 Japan
永琦東急百貨 Tokyu 臺北 臺中 1975-2002
遠東 太平洋崇光百貨 SOGO (十合) 台北 中壢 新竹 高雄 1986
新光三越百貨 Mitsukoshi 臺北 桃園 新竹 臺中 嘉義 臺南 高雄 1989
大立伊勢丹 Isetan 高雄 1991-2008
大葉高島屋 Takashimaya 臺北 1992
漢神百貨 阪神 Hanshin 高雄 1995
建台大丸百貨 Daimaru 台中 高雄 1998-2002
耐斯松屋 Matsuya 嘉義 2006
統一阪急百貨 Hankyu 高雄 台北 2007
台灣購物中心列表
日本の百貨店 阪急阪神, 大丸松坂屋, 三越伊勢丹, そごう・西武, 髙島屋グループ Group
遠東 太平洋崇光百貨 SOGO (十合) 台北 中壢 新竹 高雄 1986
新光三越百貨 Mitsukoshi 臺北 桃園 新竹 臺中 嘉義 臺南 高雄 1989
大葉高島屋 Takashimaya 臺北 1992
漢神百貨 阪神 Hanshin 高雄 1995
耐斯松屋 Matsuya 嘉義 2006
統一阪急百貨 Hankyu 高雄 台北 2007
台灣購物中心列表
日本の百貨店 阪急阪神, 大丸松坂屋, 三越伊勢丹, そごう・西武, 髙島屋グループ Group
Thursday, December 20, 2012
Gastroenterologists
Endoscopy - Colonoscopy
Andy Siu-On Yu MD Medical Board 1992 (MD) - 1995 (Internal Medicine) -1998 (Gastroenterology)
Susie Man-Chi Liu MD California Medical Board 1988 (MD) - 1991 (Internal Medicine) - 1995 (Gastroenterology)
Harvey Shak-Yeen Young California Medical Board 1979 (MD) - 1983 (Internal Medicine) - 1989 (Gastroenterology)
Andy Siu-On Yu MD Medical Board 1992 (MD) - 1995 (Internal Medicine) -1998 (Gastroenterology)
Susie Man-Chi Liu MD California Medical Board 1988 (MD) - 1991 (Internal Medicine) - 1995 (Gastroenterology)
Harvey Shak-Yeen Young California Medical Board 1979 (MD) - 1983 (Internal Medicine) - 1989 (Gastroenterology)
Sunday, December 16, 2012
Ovarian Cancer
Stanford Hospital Cancer Physicians
UCSF Medical Center Cancer Specialists
National Cancer Institute, Comprehensive Cancer Centers, Clinical Trials, Cancer Trials Support Unit,
NCI's Clinical Trials Cooperative Group Program
1. TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
2. Bevacizumab (Avastin), American Society of Clinical Oncology (ASCO)
Stanford Cancer Institute, Clinical Research Groups, Gynecology, Eligibility Flowcharts Gynecologic Cancer
National Comprehensive Cancer Network, NCCN Member Institutions, Guidelines with Evidence Blocks
NCI Ovarian Cancer Treatments - Intraperitoneal Therapy, Angiogenesis Inhibitors (Bevacizumab)
* Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review - anti-angiogenesis
List of trauma centers in the United States Adult Level I
ClinicalTrials.gov
癌症研究所－臺灣癌症臨床研究合作組織 癌症臨床指引
婦女醫學資料庫 - 卵巢癌
European Society for Medical Oncology Guideline Gynaecologic Cancers
Peritoneal Cancer Index (PCI)
2007 Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
2008 Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.
2009 Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
2009 Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
2010 Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.
2012 CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
* 2011 Ovarian Cancer Diagnosis and Treatment
Postoperative nausea and vomiting NeiGuan Pericardium Meridian 6 accupressure, Zofran (5-HT3 antagonists) + Emend
Chyle - milky bodily fluid consisting of lymph and emulsified fats, or free fatty acids (FFAs). A chyle fistula is a leakage of lymphatic fluid from the lymphatic vessels, typically accumulating in the thoracic or abdominal cavities, possibly leading to a chylothorax or chylous ascites, respectively.
HemOnc.org - A Free Hematology/Oncology Reference
Dosage:
Body Surface Area calculator 100lb 61" = 1.4 m^2
AUC (area under curve) serum creatinine (0.5-1.0) AUC6 = 460mg
全民健康保險藥品給付規定
Drugs@FDA FDA Approved Drug Products
FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications recently approved drugs
Approved Drugs, Drugs used in UK
cisplatin 1978, carboplatin 1989, taxol 1992, doxil 1995, topotecan 1996, gemzar 2006, bevacizumab 2014, olaparib 2014
*TAXOL (paclitaxel) *1992+cisplatin
西藥許可證 衛署藥製字, 衛署藥輸字 抗癌藥
PACLITAXEL Paclitaxel Shortage
太平洋紫杉醇 Taiwan price 175mg/m^2 * 1.4 = 245mg = $8000
corticosteroids, diphenhydramine, and H2 antagonists.
premedication: corticosteroids (steroid dexamethasone 20 mg [causing stomach upset and effects of dexamethasone on the proliferation and apoptosis]) PO administered approximately 12 and 6 hours before TAXOL, diphenhydramine-Benadryl (or its equivalent) 50 mg IV 30 to 60 minutes prior to TAXOL, and fast-acting acid reducer H2 antagonists (cimetidine-Tagamet 300 mg [Tagamet HB 200],ranitidine-Zantac 50 mg [Zantac 150], famotidine-Pepcid [Pepcid AC 20mg]) IV 30 to 60 minutes before TAXOL.
Neutropenia - 500 - 1000 - 1500, G-CSF - Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Tbo-filgrastim (Neutroval)
Anemia - blood transfusion, Epoetin alfa (Epogen/Procrit), Darbepoetin alfa (Aranesp) - erythropoiesis-stimulating agents (ESA) are not for cure
Thrombocytopenia -
Peripheral neuropathy - Glutamin 10g*3/day, Pyridoxine (Vitamin B6 100mg) - might affect response and remission
aluminum hydroxide and magnesium hydroxide [Maalox], Bismuth subsalicylate [Pepto-Bismol]
fast-acting acid reducer H2 antagonists: cimetidine-Tagamet 300 mg [Tagamet HB 200], famotidine-Pepcid [Pepcid AC 20mg]
Emend (aprepitant) NK1 antagonists 2003 + 5-HT3 antagonists: Zofran (Ondansetron) 1990 or Aloxi (Palonosetron) 2008 + Dexamethasone (steroid)
Epinephrine (adrenaline), corticosteroids, and antihistamines: Benadryl (diphenhydramine)
*Tamoxifen 2x20mg daily, increasing CA125
*relapsed at least 6 months after platinum-based treatment
GEMZAR (gemcitabine) *1996(non-small cell lung)-2006 (ovarian+carboplatin) last cytotoxic drug
西藥許可證 衛署藥製字, 衛署藥輸字 1.非小細胞肺癌2.胰臟癌3.膀胱癌4.乳癌5.卵巢癌
健澤, 吉西他滨 1000mg/m^2 * 1.4 * 2 = 2800mg = $13000
GEMCITABINE *
1. with carboplatin, bevacizumab (ascites) dosage C AUC4, G 1000mg/m^2 D1,D8, BEV 15mg/kg D1, q21D x 6c -> BEV q21D, Trial, recurred 6 month after maintenance, during maintenance, HE4, CA125
2. with cisplatin, bevacizumab Gemcitabine in Ovarian Cancer C 75mg/m^2, G 1250mg/m^2 D1, D8, BEV 15mg/kg D1...
*after 3 chemo
Lynparza Olaparib *2014 PARP-inhibitor for germline BRCA mutated, best for platinum sensitive, not somatic cells
400mg*2 daily, Proton pump inhibitor (Pantoprazole) or H2 antagonists for dyspepsia, diarrhea, or nausea
*platinum-resistant, first or second relapse
Bevacizumab (Avastin) *2014 (with Taxol, Gemzar, PLD, Topotecan)
癌思停 15mg/kg/3weeks * 45kg = 675mg = $65000
Seeking Alpha: Roche's Avastin Should Get The Nod From The FDA On November 19
*after platinum
DOXIL (Liposomal Doxorubicin Hydrochloride) *1995 (also multiple myeloma)
微脂體小紅莓化療藥物合併鉑金藥物, 多柔比星脂质体
康利斯微脂粒 Caelyx 50mg/m^2 * 1.4 = 70mg = $43000
Doxil with Carboplatin - 30mg/m^2 + AUC 5 (4 weekly), escalated to AUC 6 and then 40mg
Maintenance 30–40 mg/m^2 given every 4–8 weeks, heart failure after cumulative 550mg/m^2
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance
*metastatic, failure of initial and subsequent chemotherapy
HYCAMTIN (topotecan) *1996 (also cervical, small cell lung cancer) Caris no
癌康定, 托泊替康 1.5mg/m^2 * 1.4 * 5 day = 10.5mg = $21500
with Bevacizumab schedule
1, topotecan 4mg/m^2 days 1, 8, 15 every 4 weeks + Avastin 10mg every 2 weeks
2. topotecan 1.25mg/m^2 days 1-5 every 3 weeks + Avastin 15mg every 3 weeks
Etoposide trial 1983 SCLC oral 50-60mg/m2/d for 21 days per 28 days
抑特癌 50*1.4*21 = 70m2*21 = $5000
Alkylating antineoplastic agent
*Cyclophosphamide Cytoxan *1959 (malignant disease)
癌德星
-Ifosfamide *1988
-Melphalan
*Altretamine *1990
Other 3rd line
Pemetrexed Caris no
Vinorelbine
Capecitabine Caris no
Pazopanib (Votrient) tyrosine kinase inhibitor, angiogenesis inhibitor VEGF-R 800mg daily, 2009 renal, sarcoma
福退癌 200mg*4 $677 = $56868 / 3 weeks maintenance
result not as good for East Asian Women, report, bad for Asian Women, Neutropenia, thrombocytopenia and palmar-plantar erythrodysaethesia syndrome were observed more frequently in patients of East Asian descent 亞洲
Side-effect Adverse-effects:
Carbo: Nausea, Vomiting, Electrolytes (sodium, magnesium) loss, Bone Marrow (Leukopenia, Neutropenia, Thrombocytopenia) (Transfusions)
Taxol: Alopecia, Peripheral Neuropathy, Myalgia (muscle pain), Neutropenia, Nausea
Gemzar: Nausea, Hematologic (Anemia, Neutropenia), Hepatic, Proteinuria, Fever
Doxil: Hand-foot syndrome, Nausea, Stomatitis, Asthenia (fatigue)
Topotecan: Neutropenia, Nausea, Alopecia, Infections
Cancer Focus Forum: Cancer Forums and News by PhD's
Chemotherapy sensitivity/resistance assays and other biomarker assays - Inspire Cancer Focus, CSN
Human Tumor Stem Cell Drug Sensitivity Assays (190.7)
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
Precision Therapeutics, Inc. ChemoFx, Rational Therapeutics, Weisenthal Cancer Group
HIPEC
Hyperthermia therapy
Hyperthermia in Cancer Treatment
Treatment Types Hyperthermia
Hyperthermia: Using Heat to Treat Cancer
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Continuous hyperthermic peritoneal perfusion
Surgeon performs controversial cancer surgery named after him Sugarbaker
NYT: Hot Chemotherapy Bath: Patients See Hope, Critics Hold Doubts
OncLive: Chemo Controversy: An Inside Look at the 'Hot Chemotherapy Bath'
A Patient’s Guide to HIPEC
2004 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
* 2009 The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
* 2009 Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2012 Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer.
2012 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
2012 Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
2015 Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
Recurrent
2011 HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome
2012 Survival benefit of adding HIPEC at the different time-points of treatmtnt of ovarian cencer: review of evidence secondary CRS for stage III ovarian cancer and salvage CRS for recurrent ovarian cancer
2015 A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
2015 Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study
2015 The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer CRS and HIPEC offer a significant survival benefit in patients with recurrent EOC. This observation applies to both platinum-sensitive and platinum-resistant disease.
American Society of Peritoneal Surface Malignancies
Peritoneal Surface Malignancies Conference
Peritoneal Malignancies Pals
aetna: hyperthermia for cancer therapy
Cigna: hyperthermia treatment for cancer
Anthem: hyperthermia for cancer therapy
2012 Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.
Consolidation / Maintenance treatment
2003 12 versus 3 months of maintenance paclitaxel
2006 9 Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer 30–40 mg/m2 given every 4–8 weeks
** 2009 follow-up of 12 versus 3 months
** 2010 Current status of maintenance therapy for advanced ovarian cancer
2010 The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer.
2010 Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup (GCIG) and United States National Cancer Institute (NCI) clinical trials planning meeting, May, 2009
2010 Practical considerations in ovarian cancer chemotherapy
2011 Rethinking Ovarian Cancer: Recommendations for Improving Outcomes
* 2011 Current and future directions of clinical trials for ovarian cancer.
** 2011 Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach (Review).
Opaxio, Oxytax, CT-2103, Polyglutamate Paclitaxel, Paclitaxel Poliglumex
** 2011 Incorporation of bevacizumab in the primary treatment of ovarian cancer GOG-218
2012 Major clinical research advances in gynecologic cancer in 2011
2012 Therapeutic strategies in epithelial ovarian cancer
2013 Advanced ovarian cancer: what should be the standard of care?
** 2013 Role of the Microenvironment in Ovarian Cancer Stem Cell Maintenance
** 2015 Ovarian cancer standard of care: are there real alternatives?
CA125
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 response (partial) PR: 50% reduction for 4 weeks, a month; complete response CR: 35; stable disease SD; progressive disease PD
2000 Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. < 35U/mL after 3 courses
2005 A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. 400
2006 Pretreatment CA-125 and risk of relapse in advanced ovarian cancer nadir <=10 U/mL, 11-20, 21-35, PFS 24, 17, 7
2007 An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. >= 20 and double of nadir 56 days earlier
2008 CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. CA125 < or =65 U/mL before cycle 3
2008 Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer nadir <= 10 U/mL, PFS 42 vs 20, OS 84 vs 40
2008 Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer nadir < 10, 10-21, 21-35, PFS 26, 14, 10, OS 105, 42, 37
2009 Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. increase by 5 U/mL of nadir 58 days earlier
2009 Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer nadir <= 10, PFS 32.4 vs 16.8
2010 Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. > 500U/mL neo-adjuvant
2010 CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study nadir <= 5 U/mL
2010 Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
2011 Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. < 35U/mL after 3rd cycle
2011 Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
2011 Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. NLR should be less than 2.6
2011 Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. > 2000
2011 Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
2011 Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer < nadir 18 U/mL
2012 The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study doubling of value and nadir > 10
2012 Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer should be less than 200-300
Progression Free Survival
2011 Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective
2011 Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Recurrence, resistant
2016 ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells P-glycoprotein inhibitors Tariquidar
2015 Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer, Topotecan+Avastin, Docetaxel+Avastin, Pemetrexed, Nab-Paclitaxel, Etirinotecan Pegol, low-dose oral cyclophosphamide, Olaparib, Rucaparib
Platinum Resistance in Ovarian Cancer OncLive
2011 Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
2012 The Role of Secondary Surgery in Recurrent Ovarian Cancer
2013 CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery 1.68 * nadir
2013 Should studies of maintenance therapy be maintained in women with ovarian cancer?
2014 Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
2010 Weight, Physical Activity, Diet, and Prognosis in Breast and Gynecologic Cancers
2010 What surveillance plan should be advised for patients in remission after completion of first-line therapy for advanced ovarian cancer? 3, 3, 4, 6
2015 Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells
2014 Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway
2010 The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer
PARP, BRCAness, BRCA-like
2015 Olaparib in the management of ovarian cancer
2015 Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes.
2015 Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
2014 PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Metronomic
metronomic ovarian papers
2014 Metronomic chemotherapy
2013 Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
2013 The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
Immunotherapy
PD-1 Nivolumab, Pembrolizumab
2015 Immunotherapeutic approaches to ovarian cancer treatment Antibody, Immune checkpoint inhibitors, Vaccine strategies, Adoptive cell therapy, Combinatorial immunotherapy
2013 Antibody-based immunotherapy for ovarian cancer: where are we at?, trial results, Abagovomab, Oregovomab
The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
Ketogenic Diet carbohydrate restriction, metabolic therapy
2015 Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy
2014 Ketogenic diet does not “beat chemo for almost all cancers”
Thomas Seyfried Cancer as a Metabolic Disease
2014 Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism
2013 Tumor glycolysis as a target for cancer therapy: progress and prospects
2011 Is there a role for carbohydrate restriction in the treatment and prevention of cancer?
Women's Cancer Network, Find a Gynecologic Oncologist
台灣婦癌醫學會, 專科醫師名單, 成員服務醫院
台灣癌症臨床研究發展基金會
KingNet 國家網路醫院
日本婦人科腫瘍学会 卵巣がん治療ガイドライン
UCSF Medical Center Cancer Specialists
National Cancer Institute, Comprehensive Cancer Centers, Clinical Trials, Cancer Trials Support Unit,
NCI's Clinical Trials Cooperative Group Program
1. TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
2. Bevacizumab (Avastin), American Society of Clinical Oncology (ASCO)
Stanford Cancer Institute, Clinical Research Groups, Gynecology, Eligibility Flowcharts Gynecologic Cancer
National Comprehensive Cancer Network, NCCN Member Institutions, Guidelines with Evidence Blocks
NCI Ovarian Cancer Treatments - Intraperitoneal Therapy, Angiogenesis Inhibitors (Bevacizumab)
* Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review - anti-angiogenesis
List of trauma centers in the United States Adult Level I
ClinicalTrials.gov
癌症研究所－臺灣癌症臨床研究合作組織 癌症臨床指引
婦女醫學資料庫 - 卵巢癌
European Society for Medical Oncology Guideline Gynaecologic Cancers
Peritoneal Cancer Index (PCI)
2007 Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
2008 Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.
2009 Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
2009 Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
2010 Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.
2012 CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
* 2011 Ovarian Cancer Diagnosis and Treatment
Postoperative nausea and vomiting NeiGuan Pericardium Meridian 6 accupressure, Zofran (5-HT3 antagonists) + Emend
Chyle - milky bodily fluid consisting of lymph and emulsified fats, or free fatty acids (FFAs). A chyle fistula is a leakage of lymphatic fluid from the lymphatic vessels, typically accumulating in the thoracic or abdominal cavities, possibly leading to a chylothorax or chylous ascites, respectively.
HemOnc.org - A Free Hematology/Oncology Reference
Dosage:
Body Surface Area calculator 100lb 61" = 1.4 m^2
AUC (area under curve) serum creatinine (0.5-1.0) AUC6 = 460mg
全民健康保險藥品給付規定
Drugs@FDA FDA Approved Drug Products
FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications recently approved drugs
Approved Drugs, Drugs used in UK
cisplatin 1978, carboplatin 1989, taxol 1992, doxil 1995, topotecan 1996, gemzar 2006, bevacizumab 2014, olaparib 2014
*TAXOL (paclitaxel) *1992+cisplatin
西藥許可證 衛署藥製字, 衛署藥輸字 抗癌藥
PACLITAXEL Paclitaxel Shortage
太平洋紫杉醇 Taiwan price 175mg/m^2 * 1.4 = 245mg = $8000
corticosteroids, diphenhydramine, and H2 antagonists.
premedication: corticosteroids (steroid dexamethasone 20 mg [causing stomach upset and effects of dexamethasone on the proliferation and apoptosis]) PO administered approximately 12 and 6 hours before TAXOL, diphenhydramine-Benadryl (or its equivalent) 50 mg IV 30 to 60 minutes prior to TAXOL, and fast-acting acid reducer H2 antagonists (cimetidine-Tagamet 300 mg [Tagamet HB 200],
Neutropenia - 500 - 1000 - 1500, G-CSF - Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Tbo-filgrastim (Neutroval)
Anemia - blood transfusion, Epoetin alfa (Epogen/Procrit), Darbepoetin alfa (Aranesp) - erythropoiesis-stimulating agents (ESA) are not for cure
Thrombocytopenia -
Peripheral neuropathy - Glutamin 10g*3/day, Pyridoxine (Vitamin B6 100mg) - might affect response and remission
aluminum hydroxide and magnesium hydroxide [Maalox], Bismuth subsalicylate [Pepto-Bismol]
fast-acting acid reducer H2 antagonists: cimetidine-Tagamet 300 mg [Tagamet HB 200], famotidine-Pepcid [Pepcid AC 20mg]
slow-acting Proton pump inhibitor (H2 antagonists) (Omeprazole [Prilosec OTC, Zegerid OTC])
European Human Medicines for Ovarian Neoplasms: Avastin (bevacizumab) and others
*ABRAXANE nab-paclitaxel protein-bound particles albumin-bound, 2005 breast, NSCLC
*TAXOTERE (docetaxel) breast, 1999 NSCLC, prostate, ..
歐洲紫杉醇 75mg/m^2 * 1.4 = 105mg = $21000
Cynviloq paclitaxel polymeric micelle in trial
*PARAPLATIN (carboplatin) *1989+cyclophosphamide
西藥許可證 衛署藥製字, 衛署藥輸字 卵巢癌
Carboplatin shortage
佳鉑帝 Taiwan price 460mg = $4000
allergic reactions - epinephrine (adrenaline), corticosteroid (dexamethasone), and antihistamine therapy: Benadryl (diphenhydramine)
Chemotherapy-induced nausea and vomiting (emesis) 24 hour premedication: antiemetics - 5-HT3 antagonists: Zofran (Ondansetron) 1990, Aloxi (Palonosetron delayed CINV 2-5 days) 2008 + Emend 2003; Dopamine antagonist Reglan metoclopramide (older)
*CISPLATIN *1978+cyclophosphamide [ETHYOL (amifostine) reducing renal toxicity]
西藥許可證 衛署藥輸字 轉移性睪丸腫瘤,轉移性卵巢腫瘤,膀胱內轉移型細胞腫瘤
順鉑 Taiwan price 75mg/m^2 * 1.4 = 105mg = $400
PLATINOL (cisplatin) Guidelines for Hospitalization for Chemotherapy outpatient 75mg/m^2
Mannitol
European Human Medicines for Ovarian Neoplasms: Avastin (bevacizumab) and others
*ABRAXANE nab-paclitaxel protein-bound particles albumin-bound, 2005 breast, NSCLC
*TAXOTERE (docetaxel) breast, 1999 NSCLC, prostate, ..
歐洲紫杉醇 75mg/m^2 * 1.4 = 105mg = $21000
Cynviloq paclitaxel polymeric micelle in trial
*PARAPLATIN (carboplatin) *1989+cyclophosphamide
西藥許可證 衛署藥製字, 衛署藥輸字 卵巢癌
Carboplatin shortage
佳鉑帝 Taiwan price 460mg = $4000
allergic reactions - epinephrine (adrenaline), corticosteroid (dexamethasone), and antihistamine therapy: Benadryl (diphenhydramine)
Chemotherapy-induced nausea and vomiting (emesis) 24 hour premedication: antiemetics - 5-HT3 antagonists: Zofran (Ondansetron) 1990, Aloxi (Palonosetron delayed CINV 2-5 days) 2008 + Emend 2003; Dopamine antagonist Reglan metoclopramide (older)
*CISPLATIN *1978+cyclophosphamide [ETHYOL (amifostine) reducing renal toxicity]
西藥許可證 衛署藥輸字 轉移性睪丸腫瘤,轉移性卵巢腫瘤,膀胱內轉移型細胞腫瘤
順鉑 Taiwan price 75mg/m^2 * 1.4 = 105mg = $400
PLATINOL (cisplatin) Guidelines for Hospitalization for Chemotherapy outpatient 75mg/m^2
Mannitol
Emend (aprepitant) NK1 antagonists 2003 + 5-HT3 antagonists: Zofran (Ondansetron) 1990 or Aloxi (Palonosetron) 2008 + Dexamethasone (steroid)
Epinephrine (adrenaline), corticosteroids, and antihistamines: Benadryl (diphenhydramine)
*Tamoxifen 2x20mg daily, increasing CA125
*relapsed at least 6 months after platinum-based treatment
GEMZAR (gemcitabine) *1996(non-small cell lung)-2006 (ovarian+carboplatin) last cytotoxic drug
西藥許可證 衛署藥製字, 衛署藥輸字 1.非小細胞肺癌2.胰臟癌3.膀胱癌4.乳癌5.卵巢癌
健澤, 吉西他滨 1000mg/m^2 * 1.4 * 2 = 2800mg = $13000
GEMCITABINE *
1. with carboplatin, bevacizumab (ascites) dosage C AUC4, G 1000mg/m^2 D1,D8, BEV 15mg/kg D1, q21D x 6c -> BEV q21D, Trial, recurred 6 month after maintenance, during maintenance, HE4, CA125
2. with cisplatin, bevacizumab Gemcitabine in Ovarian Cancer C 75mg/m^2, G 1250mg/m^2 D1, D8, BEV 15mg/kg D1...
*after 3 chemo
Lynparza Olaparib *2014 PARP-inhibitor for germline BRCA mutated, best for platinum sensitive, not somatic cells
400mg*2 daily, Proton pump inhibitor (Pantoprazole) or H2 antagonists for dyspepsia, diarrhea, or nausea
*platinum-resistant, first or second relapse
Bevacizumab (Avastin) *2014 (with Taxol, Gemzar, PLD, Topotecan)
癌思停 15mg/kg/3weeks * 45kg = 675mg = $65000
Seeking Alpha: Roche's Avastin Should Get The Nod From The FDA On November 19
*after platinum
DOXIL (Liposomal Doxorubicin Hydrochloride) *1995 (also multiple myeloma)
微脂體小紅莓化療藥物合併鉑金藥物, 多柔比星脂质体
康利斯微脂粒 Caelyx 50mg/m^2 * 1.4 = 70mg = $43000
Doxil with Carboplatin - 30mg/m^2 + AUC 5 (4 weekly), escalated to AUC 6 and then 40mg
Maintenance 30–40 mg/m^2 given every 4–8 weeks, heart failure after cumulative 550mg/m^2
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance
*metastatic, failure of initial and subsequent chemotherapy
HYCAMTIN (topotecan) *1996 (also cervical, small cell lung cancer) Caris no
癌康定, 托泊替康 1.5mg/m^2 * 1.4 * 5 day = 10.5mg = $21500
with Bevacizumab schedule
1, topotecan 4mg/m^2 days 1, 8, 15 every 4 weeks + Avastin 10mg every 2 weeks
2. topotecan 1.25mg/m^2 days 1-5 every 3 weeks + Avastin 15mg every 3 weeks
Etoposide trial 1983 SCLC oral 50-60mg/m2/d for 21 days per 28 days
抑特癌 50*1.4*21 = 70m2*21 = $5000
Alkylating antineoplastic agent
*Cyclophosphamide Cytoxan *1959 (malignant disease)
癌德星
-Ifosfamide *1988
-Melphalan
*Altretamine *1990
Other 3rd line
Pemetrexed Caris no
Vinorelbine
Capecitabine Caris no
Pazopanib (Votrient) tyrosine kinase inhibitor, angiogenesis inhibitor VEGF-R 800mg daily, 2009 renal, sarcoma
福退癌 200mg*4 $677 = $56868 / 3 weeks maintenance
result not as good for East Asian Women, report, bad for Asian Women, Neutropenia, thrombocytopenia and palmar-plantar erythrodysaethesia syndrome were observed more frequently in patients of East Asian descent 亞洲
Side-effect Adverse-effects:
Carbo: Nausea, Vomiting, Electrolytes (sodium, magnesium) loss, Bone Marrow (Leukopenia, Neutropenia, Thrombocytopenia) (Transfusions)
Taxol: Alopecia, Peripheral Neuropathy, Myalgia (muscle pain), Neutropenia, Nausea
Gemzar: Nausea, Hematologic (Anemia, Neutropenia), Hepatic, Proteinuria, Fever
Doxil: Hand-foot syndrome, Nausea, Stomatitis, Asthenia (fatigue)
Topotecan: Neutropenia, Nausea, Alopecia, Infections
Cancer Focus Forum: Cancer Forums and News by PhD's
Chemotherapy sensitivity/resistance assays and other biomarker assays - Inspire Cancer Focus, CSN
Human Tumor Stem Cell Drug Sensitivity Assays (190.7)
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
Precision Therapeutics, Inc. ChemoFx, Rational Therapeutics, Weisenthal Cancer Group
HIPEC
Hyperthermia therapy
Hyperthermia in Cancer Treatment
Treatment Types Hyperthermia
Hyperthermia: Using Heat to Treat Cancer
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Continuous hyperthermic peritoneal perfusion
Surgeon performs controversial cancer surgery named after him Sugarbaker
NYT: Hot Chemotherapy Bath: Patients See Hope, Critics Hold Doubts
OncLive: Chemo Controversy: An Inside Look at the 'Hot Chemotherapy Bath'
A Patient’s Guide to HIPEC
2004 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
* 2009 The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
* 2009 Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2012 Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer.
2012 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
2012 Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
2015 Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
Recurrent
2011 HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome
2012 Survival benefit of adding HIPEC at the different time-points of treatmtnt of ovarian cencer: review of evidence secondary CRS for stage III ovarian cancer and salvage CRS for recurrent ovarian cancer
2015 A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
2015 Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study
2015 The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer CRS and HIPEC offer a significant survival benefit in patients with recurrent EOC. This observation applies to both platinum-sensitive and platinum-resistant disease.
American Society of Peritoneal Surface Malignancies
Peritoneal Surface Malignancies Conference
Peritoneal Malignancies Pals
aetna: hyperthermia for cancer therapy
Cigna: hyperthermia treatment for cancer
Anthem: hyperthermia for cancer therapy
2012 Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.
Consolidation / Maintenance treatment
2003 12 versus 3 months of maintenance paclitaxel
2006 9 Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer 30–40 mg/m2 given every 4–8 weeks
** 2009 follow-up of 12 versus 3 months
** 2010 Current status of maintenance therapy for advanced ovarian cancer
2010 The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer.
2010 Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup (GCIG) and United States National Cancer Institute (NCI) clinical trials planning meeting, May, 2009
2010 Practical considerations in ovarian cancer chemotherapy
2011 Rethinking Ovarian Cancer: Recommendations for Improving Outcomes
* 2011 Current and future directions of clinical trials for ovarian cancer.
** 2011 Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach (Review).
Opaxio, Oxytax, CT-2103, Polyglutamate Paclitaxel, Paclitaxel Poliglumex
** 2011 Incorporation of bevacizumab in the primary treatment of ovarian cancer GOG-218
2012 Major clinical research advances in gynecologic cancer in 2011
2012 Therapeutic strategies in epithelial ovarian cancer
2013 Advanced ovarian cancer: what should be the standard of care?
** 2013 Role of the Microenvironment in Ovarian Cancer Stem Cell Maintenance
** 2015 Ovarian cancer standard of care: are there real alternatives?
CA125
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 response (partial) PR: 50% reduction for 4 weeks, a month; complete response CR: 35; stable disease SD; progressive disease PD
2000 Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. < 35U/mL after 3 courses
2005 A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. 400
2006 Pretreatment CA-125 and risk of relapse in advanced ovarian cancer nadir <=10 U/mL, 11-20, 21-35, PFS 24, 17, 7
2007 An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. >= 20 and double of nadir 56 days earlier
2008 CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. CA125 < or =65 U/mL before cycle 3
2008 Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer nadir <= 10 U/mL, PFS 42 vs 20, OS 84 vs 40
2008 Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer nadir < 10, 10-21, 21-35, PFS 26, 14, 10, OS 105, 42, 37
2009 Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. increase by 5 U/mL of nadir 58 days earlier
2009 Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer nadir <= 10, PFS 32.4 vs 16.8
2010 Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. > 500U/mL neo-adjuvant
2010 CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study nadir <= 5 U/mL
2010 Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
2011 Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. < 35U/mL after 3rd cycle
2011 Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
2011 Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. NLR should be less than 2.6
2011 Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. > 2000
2011 Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
2011 Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer < nadir 18 U/mL
2012 The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study doubling of value and nadir > 10
2012 Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer should be less than 200-300
Progression Free Survival
2011 Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective
2011 Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Recurrence, resistant
2016 ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells P-glycoprotein inhibitors Tariquidar
2015 Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer, Topotecan+Avastin, Docetaxel+Avastin, Pemetrexed, Nab-Paclitaxel, Etirinotecan Pegol, low-dose oral cyclophosphamide, Olaparib, Rucaparib
Platinum Resistance in Ovarian Cancer OncLive
2011 Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
2012 The Role of Secondary Surgery in Recurrent Ovarian Cancer
2013 CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery 1.68 * nadir
2013 Should studies of maintenance therapy be maintained in women with ovarian cancer?
2014 Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
2010 Weight, Physical Activity, Diet, and Prognosis in Breast and Gynecologic Cancers
2010 What surveillance plan should be advised for patients in remission after completion of first-line therapy for advanced ovarian cancer? 3, 3, 4, 6
2015 Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells
2014 Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway
2010 The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer
PARP, BRCAness, BRCA-like
2015 Olaparib in the management of ovarian cancer
2015 Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes.
2015 Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
2014 PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Metronomic
metronomic ovarian papers
2014 Metronomic chemotherapy
2013 Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
2013 The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
Immunotherapy
PD-1 Nivolumab, Pembrolizumab
2015 Immunotherapeutic approaches to ovarian cancer treatment Antibody, Immune checkpoint inhibitors, Vaccine strategies, Adoptive cell therapy, Combinatorial immunotherapy
2013 Antibody-based immunotherapy for ovarian cancer: where are we at?, trial results, Abagovomab, Oregovomab
The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
Ketogenic Diet carbohydrate restriction, metabolic therapy
2015 Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy
2014 Ketogenic diet does not “beat chemo for almost all cancers”
Thomas Seyfried Cancer as a Metabolic Disease
2014 Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism
2013 Tumor glycolysis as a target for cancer therapy: progress and prospects
2011 Is there a role for carbohydrate restriction in the treatment and prevention of cancer?
Women's Cancer Network, Find a Gynecologic Oncologist
台灣婦癌醫學會, 專科醫師名單, 成員服務醫院
台灣癌症臨床研究發展基金會
KingNet 國家網路醫院
日本婦人科腫瘍学会 卵巣がん治療ガイドライン
Thursday, December 13, 2012
Low Cost or Free Voice over IP
Voice over IP
magicJack vs netTALK vs Ooma vs. Obihai
Obihai deals
Dial **8 for PSTN Line Port Service Provider
Google Voice free, 1c/min Google Voice: port landline number
Localphone 0.5c/min, Android, iOS apps 5min free
netTalk DUO free first year, $2.5/month, $29.95/year+tax, Android (phone), iOS apps free 50 min/month
MagicJack Plus free test drive, $19.99/year to $29.95/year, Android, iOS apps
Skype phone 2.3c/min $2.99/month, $5/month premium, free 30 day Premium with Unlimited World trial
magicJack vs netTALK vs Ooma vs. Obihai
Obihai deals
Dial **8 for PSTN Line Port Service Provider
Google Voice free, 1c/min Google Voice: port landline number
Localphone 0.5c/min, Android, iOS apps 5min free
netTalk DUO free first year, $2.5/month, $29.95/year+tax, Android (phone), iOS apps free 50 min/month
MagicJack Plus free test drive, $19.99/year to $29.95/year, Android, iOS apps
Skype phone 2.3c/min $2.99/month, $5/month premium, free 30 day Premium with Unlimited World trial
Friday, December 07, 2012
Colon and Rectal Surgeons
American Board of Colon and Rectal Surgery, Directory of Diplomates
Segall, Mark USA CA Los Gatos MD 1980 No
Doria, Miguel USA CA San Jose MD 1980 No
Coughlin, Richard USA CA Los Gatos MD 1992 2022 Yes
Hobson, Kristina USA CA Los Gatos MD 2005 2015 Yes
Wang, Jennifer USA CA San Jose MD 2011 2021 No
Segall, Mark USA CA Los Gatos MD 1980 No
Doria, Miguel USA CA San Jose MD 1980 No
Coughlin, Richard USA CA Los Gatos MD 1992 2022 Yes
Hobson, Kristina USA CA Los Gatos MD 2005 2015 Yes
Wang, Jennifer USA CA San Jose MD 2011 2021 No
Wednesday, November 28, 2012
DSLR cameras for video/movie filming
Power Zoom Lens,
Nikon 1 10-100mm (YouTube), no focus ring
Panasonic 14-42mm, 45-175mm (YouTube)
Focus Peaking, Sony NEX, Pentax K-01, K-30, Olympus E-M5, Magic Lantern for Canon 5D Mark II, T3i, T2i, MagicLantern features, firmware hack, Magic Lantern Detailed Build Features (EOS T4i, 70D have dual-pixel continuous autofocus), EOS-M shutter bug
(use SanDisk Extreme 32GB)
SD UHS Hack:
The Original Canon EOS M Can Shoot 2.5K Raw Video with Magic Lantern
, Canon EOS M, UHS-I / SD cards investigation, download
** dpreview lightweight with external microphone port/jack fully articulated or tilting LCD, touch screen: Canon EOS M50, M6, M3, Fujifilm X-A4
Large sensor with touch screen
dpreview comparison of small mirrorless
dxomark of small mirrorless Sony A5000 > Olympus E-PM2 > Panasonic DMC-GM1
dxo mark of Sony NEX A5000, NEX-5T, NEX-5R
Sony Alpha a5100, Sony Alpha NEX-5T, Sony Alpha NEX-5R, Canon EOS M, Sony Alpha NEX-5N, Canon EOS M3 comparison of mirrorless with touch screen
- Sony a5100 8/2014, 25 contrast-detection & 179 phase-detection detection hybrid AF $700
- NEX-5T 8/2013, 25 contrast, 99 phase $700 - $500
-- E PZ 16-50mm f3.5-5.6 OSS 29.9mm
-- E PZ 18-200mm f3.5-6.3 OSS
-- E PZ 18-105mm f4 G OSS powerzoom
-- E 20mm F2.8 20.4mm
- Nikon 1 J4 4/2014 $600
-- 1 Nikkor VR 10-100mm f4.5-5.6 PD Zoom
- Olympus Pen E-PL7 8/2014 81 focusing points $700
- E-PM2 9/2012, lightweight, has 35 focus points $600 - $300
- E-M1 9/2013, has 81 + 37 phase difference detection $1300
-- electric zoom lens Olympus M.Zuiko ED 12-50mm f3.5-6.3 EZ, ED 14-42mm f3.5-5.6 EZ
- Panasonic DMC-GM1 10/2013 23 focus points, compact/small $750 - $600
- DMC GF6 4/2013 $600 - $450
-- LUMIX G X VARIO PZ 14-42mm F3.5-5.6
-- LUMIX G X VARIO PZ 45-175mm F4.0-5.6
- Canon EOS Rebel SL1, Hybrid CMOS AF II, CMOS sensor technology
- Canon EOS M hot shoe for external microphone and flash 7/2012 $850 - $250 10.86 x 6.65 x 5.6, 9.23 (4.28 x 2.62 x 2.2 [2.5 with cap], 3.63 [3.93 with cap])
-- fix 22mm lens 10.86 x 6.65 x 6.35 (4.28 x 2.62 x 2.5)
*-- case logic Medium Camera Case CPL-102
**-- Lowepro Dashpoint 20 $10
--- tamrac Pro Compact Digital
--- case logic Medium Camera Case TBC-403 no belt
-- fix 18-55mm lens 10.86 x 6.65 x 10 (4.28 x 2.62 x 3.93)
-- case logic high zoom / compact system camera case CPL-103
*-- case logic camcorder kit bag QPB-203
**-- Loewpro Adventura Ultra Zoom 100 $15
**-- Lowepro Dashpoint 30 $15
-- fix SLR lens
**-- tamrac AERO 94
-- case logic DCB-314 DCB-304
-- EF-M 18-55mm f3.5-5.6 IS STM
-- EF-M 22mm f/2 STM 23.7mm
Canon EOS digital cameras 5D mark II, 50D, 60D, T1i 500D, T2i 550D and T3i 600D
70D has dual pixel phase detection Auto-Focus PDAF, best for live view
M, T4i (650D), T5i (700D) has continuous autofocus with Digic 5 and Hybrid CMOS AF
SL1 (100D), M2 has Hybrid CMOS AF II, Northlight Images, The New Camera
SL2 (150D): Northlight Images, The New Camera, camyx
Rolling shutter, CCD, CMOS sensors
Linear motor instead of stepping motor
Parfocal lens, Sony 18-200mm
Lens breathing
External Microphone
Viewfinder, Exchangeable lens
Nikon 1 10-100mm (YouTube), no focus ring
Panasonic 14-42mm, 45-175mm (YouTube)
Focus Peaking, Sony NEX, Pentax K-01, K-30, Olympus E-M5, Magic Lantern for Canon 5D Mark II, T3i, T2i, MagicLantern features, firmware hack, Magic Lantern Detailed Build Features (EOS T4i, 70D have dual-pixel continuous autofocus), EOS-M shutter bug
(use SanDisk Extreme 32GB)
SD UHS Hack:
The Original Canon EOS M Can Shoot 2.5K Raw Video with Magic Lantern
, Canon EOS M, UHS-I / SD cards investigation, download
** dpreview lightweight with external microphone port/jack fully articulated or tilting LCD, touch screen: Canon EOS M50, M6, M3, Fujifilm X-A4
Large sensor with touch screen
dpreview comparison of small mirrorless
dxomark of small mirrorless Sony A5000 > Olympus E-PM2 > Panasonic DMC-GM1
dxo mark of Sony NEX A5000, NEX-5T, NEX-5R
Sony Alpha a5100, Sony Alpha NEX-5T, Sony Alpha NEX-5R, Canon EOS M, Sony Alpha NEX-5N, Canon EOS M3 comparison of mirrorless with touch screen
- Sony a5100 8/2014, 25 contrast-detection & 179 phase-detection detection hybrid AF $700
- NEX-5T 8/2013, 25 contrast, 99 phase $700 - $500
-- E PZ 16-50mm f3.5-5.6 OSS 29.9mm
-- E PZ 18-200mm f3.5-6.3 OSS
-- E PZ 18-105mm f4 G OSS powerzoom
-- E 20mm F2.8 20.4mm
- Nikon 1 J4 4/2014 $600
-- 1 Nikkor VR 10-100mm f4.5-5.6 PD Zoom
- Olympus Pen E-PL7 8/2014 81 focusing points $700
- E-PM2 9/2012, lightweight, has 35 focus points $600 - $300
- E-M1 9/2013, has 81 + 37 phase difference detection $1300
-- electric zoom lens Olympus M.Zuiko ED 12-50mm f3.5-6.3 EZ, ED 14-42mm f3.5-5.6 EZ
- Panasonic DMC-GM1 10/2013 23 focus points, compact/small $750 - $600
- DMC GF6 4/2013 $600 - $450
-- LUMIX G X VARIO PZ 14-42mm F3.5-5.6
-- LUMIX G X VARIO PZ 45-175mm F4.0-5.6
- Canon EOS Rebel SL1, Hybrid CMOS AF II, CMOS sensor technology
- Canon EOS M hot shoe for external microphone and flash 7/2012 $850 - $250 10.86 x 6.65 x 5.6, 9.23 (4.28 x 2.62 x 2.2 [2.5 with cap], 3.63 [3.93 with cap])
-- fix 22mm lens 10.86 x 6.65 x 6.35 (4.28 x 2.62 x 2.5)
*-- case logic Medium Camera Case CPL-102
**-- Lowepro Dashpoint 20 $10
--- tamrac Pro Compact Digital
--- case logic Medium Camera Case TBC-403 no belt
-- fix 18-55mm lens 10.86 x 6.65 x 10 (4.28 x 2.62 x 3.93)
-- case logic high zoom / compact system camera case CPL-103
*-- case logic camcorder kit bag QPB-203
**-- Loewpro Adventura Ultra Zoom 100 $15
**-- Lowepro Dashpoint 30 $15
-- fix SLR lens
**-- tamrac AERO 94
-- case logic DCB-314 DCB-304
-- EF-M 18-55mm f3.5-5.6 IS STM
-- EF-M 22mm f/2 STM 23.7mm
Canon EOS digital cameras 5D mark II, 50D, 60D, T1i 500D, T2i 550D and T3i 600D
70D has dual pixel phase detection Auto-Focus PDAF, best for live view
M, T4i (650D), T5i (700D) has continuous autofocus with Digic 5 and Hybrid CMOS AF
SL1 (100D), M2 has Hybrid CMOS AF II, Northlight Images, The New Camera
SL2 (150D): Northlight Images, The New Camera, camyx
Rolling shutter, CCD, CMOS sensors
Linear motor instead of stepping motor
Parfocal lens, Sony 18-200mm
Lens breathing
External Microphone
Viewfinder, Exchangeable lens
Sunday, November 11, 2012
California Certified Air Cleaning Devices
http://www.arb.ca.gov/research/indoor/ozone.htm
Safe ozone level and ions, ionized air purifier, ionization control, ozone generator.
Safe ozone level and ions, ionized air purifier, ionization control, ozone generator.
Thursday, November 08, 2012
Tuesday, November 06, 2012
Top Retailers / Stores
Top 100 Retailers, Favorite 50 (online), Top 250 Global Retailers
中国连锁百强 中国连锁经营协会 Chinese Merchants
China Top 100 Chain Retailers (CCSFA, China Chain Store & Franchise Association)
中国连锁百强 中国连锁经营协会 Chinese Merchants
China Top 100 Chain Retailers (CCSFA, China Chain Store & Franchise Association)
Saturday, November 03, 2012
Apple system on chips and iOS
Apple system on chips
A4 45nm 1-core SGX535
iPad, iPhone 4, iPod Touch 4th, Apple TV 2nd Gen
A5 45nm 2-core SGX543MP2
iPad 2, iPhone 4S 2011
A5 32nm 2-core SGX543MP2
iPad 2,4, iPod Touch 5th Gen, iPad mini, Apple TV 3rd Gen
A5X 45nm 2-core SGX543MP4
iPad 3rd Gen
A6 32nm 2-core SGX543MP3
iPhone 5, 5C
A6X 32nm 2-core SGX554MP4
iPad 4th Gen
A7 28nm 2-core G6430 quad core
iPad Air, iPhone 5S, iPad mini 2, 3, 2013
A8 20nm 2-core GX6450 quad core
iPhone 6, iPod Touch 6th, iPad mini 4, Apple TV 4th
A8X 20nm 3-core GXA6850 octa core
iPad Air 2 2014
A9 16nm 2-core GT7600 hexa core
iPhone 6S, SE
A9X 16nm 2-core 7XT dodeca 12 core
iPad Pro
A10 16nm 4-core hexa core
iPhone 7
Apple iOS
iOS included applications for iPhone, iPod Touch, iPad, iPad mini
A4 45nm 1-core SGX535
iPad, iPhone 4, iPod Touch 4th, Apple TV 2nd Gen
A5 45nm 2-core SGX543MP2
iPad 2, iPhone 4S 2011
A5 32nm 2-core SGX543MP2
iPad 2,4, iPod Touch 5th Gen, iPad mini, Apple TV 3rd Gen
A5X 45nm 2-core SGX543MP4
iPad 3rd Gen
A6 32nm 2-core SGX543MP3
iPhone 5, 5C
A6X 32nm 2-core SGX554MP4
iPad 4th Gen
A7 28nm 2-core G6430 quad core
iPad Air, iPhone 5S, iPad mini 2, 3, 2013
A8 20nm 2-core GX6450 quad core
iPhone 6, iPod Touch 6th, iPad mini 4, Apple TV 4th
A8X 20nm 3-core GXA6850 octa core
iPad Air 2 2014
A9 16nm 2-core GT7600 hexa core
iPhone 6S, SE
A9X 16nm 2-core 7XT dodeca 12 core
iPad Pro
A10 16nm 4-core hexa core
iPhone 7
Apple iOS
iOS included applications for iPhone, iPod Touch, iPad, iPad mini
Subscribe to:
Posts (Atom)